Oral administration of 60 and 180 mg/kg of this product to mice had no significant effect on the central nervous system, and no synergistic effect was observed when used in combination with anesthetics; oral administration of 120 mg/kg and 240 mg/kg of this product to dogs had no significant effect on heart rate, electrocardiogram and respiration compared with before administration. The results of toxicological studies showed that: 1 Acute toxicity: The LD50 of this product for mice taken orally once was 1972.7 mg/kg for males and 1882.4 mg/kg for females; the LD50 of this product for rats taken orally was greater than 4000 mg/kg; the LD50 of this product for dogs taken orally was greater than 4500 mg/kg. 2 Reproductive toxicity: When mice were gavaged with 200-600 mg/kg of this product, no significant toxicity or teratogenic effect was observed on pregnant mice and embryos. 3 Mutagenicity: No mutagenicity was observed in microbial reverse mutation test, Chinese hamster lung cell chromosome aberration test and mouse bone marrow micronucleus test. 4 Long-term toxicity: Rats were orally administered with 40, 500 and 1000 mg/kg.d for two consecutive months. Except for a temporary increase in transaminase at 1000 mg/kg.d, no other functional and pathological changes were observed. 40 and 500 mg/kg.d are safe doses. Dogs were orally administered with 35, 88 and 220 mg/kg.d for two consecutive months. Except for vomiting and increased transaminase at medium and high doses, no obvious pathological changes were observed in other biochemical functions and pathological sections.

Dirithromycin is a macrolide antibiotic, and its mechanism of action is to inhibit protein synthesis by binding to the 50S ribosomal subunit of sensitive microorganisms. It is active against aerobic Gram-positive microorganisms (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes), aerobic Gram-negative microorganisms (such as Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis) and other microorganisms (such as Mycoplasma pneumoniae). In vitro tests also show that it is active against Listeria monocytogenes, Staphylococcus (C.F.G group), Bordetella pertussis, Propionibacterium acnes, etc. Bacteria resistant to other macrolide antibiotics are also resistant to this product.

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects. Its mechanism of action is not yet fully understood, but it may be mainly related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.

This product is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic effects. Its mechanism of action may be related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects. Its mechanism of action is not yet fully understood, but it may be mainly related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.